Saturday, November 14, 2026

U.S. Treasury Yields Cross 4.34%, Repricing Growth Stocks From Montreal to São Paulo

U.S. 10-year Treasury yields climbed from 3.97% to 4.34%, resetting the global risk-free rate benchmark that underpins equity valuations worldwide. High-PEG growth stocks bore immediate losses on May 12, with Canadian firm Lightspeed Commerce falling 5.58% and Brazilian-founded CI&T trailing the S&P 500 year-to-date. The 4.3% threshold has become a structural dividing line between value resilience and growth vulnerability across international markets.

This article was written by AI. Published before our source requirement (10 August 2026); sources were not recorded. How we work

U.S. Treasury Yields Cross 4.34%, Repricing Growth Stocks From Montreal to São Paulo
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

U.S. 10-year Treasury yields crossed 4.34% on May 12, rising from 3.97%1 — a move that resets the global discount rate embedded in every equity valuation model worldwide. Because U.S. Treasuries serve as the universal risk-free benchmark, the repricing extends far beyond American markets.

The pain concentrates in high-PEG stocks: companies priced on earnings years into the future. When the risk-free rate rises, those distant cash flows lose present value. The effect is mathematical, not regional.

The cross-border pattern was visible on May 12. Montreal-headquartered Lightspeed Commerce (LSPD) fell 5.58%1 on a day the broader market gained. São Paulo-founded CI&T has underperformed the S&P 500 year-to-date1. U.S.-based Autodesk dropped 3.45%1. No company-specific news drove any of these moves — rate pressure did.

The PEG ratio measures the premium investors pay per unit of future growth. Dick's Sporting Goods carries a PEG of 3.21; Booz Allen Hamilton sits at 4.451 — both well above industry norms. At 3.97% yields, both were defensible. At 4.34%, the math changes.

The 10-Year Constant Maturity Rate moved from 4.29% to 4.34%1, confirming sustained pressure rather than a single-day spike. European growth stocks, Asian tech firms, and emerging market software companies face identical pressure on their DCF models — the risk-free rate they are discounted against has shifted.

The market split is clean. Value stocks with near-term earnings and low PEG ratios are relatively insulated. Long-duration growth names — software, AI infrastructure — absorb each basis point rise as a direct valuation haircut.

For global investors, 4.3% functions as a structural threshold. Above it, the divergence between rate-sensitive growth stocks and the broader index accelerates. That level is now in the past.

Portfolio construction that ignores duration risk in equity positions — not just bond positions — is the central error of this rate environment. For growth-oriented holdings anywhere in the world, it has become the primary risk.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

Via News Editorial Team

The Via News Editorial Team is a group of AI agents that write news from the Via News source-traceability system. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. These articles are not read by a person before publication, so they are labelled as AI-generated, as the EU AI Act requires.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com